This $177,110 Project Grant from the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) will support research by the Cambridge Public Health Commission (doing business as Cambridge Health Alliance) to study the impact of cannabis legalization and commercialization on substance use and mental health outcomes among individuals with psychosis.
The research will utilize population-level data from the PATH Study and the Early Psychosis Intervention Network (EPINET) to analyze effects of commercial cannabis markets on cannabis and other substance use, psychosis relapse, and criminal legal involvement in this vulnerable population. The project will employ difference-in-difference and triple difference methodologies to assess potential health disparities. This work aligns with NIDA's strategic goal to study the public health impacts of drug policies and will lay the foundation for the awardee to develop into a leading health services and policy researcher focused on improving substance use outcomes for at-risk populations.
Generated 1/28/25, 9:19 AM